Oppenheimer & Co’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$550K Buy
+61,070
New +$964K 0.01% 1152
2025
Q4
Sell
-49,230
Closed -$722K 1534
2025
Q3
$722K Buy
49,230
+835
+2% +$14.3K 0.01% 1041
2025
Q2
$881K Sell
48,395
-6,892
-12% -$141K 0.01% 914
2025
Q1
$1.1M Buy
55,287
+16,871
+44% +$292K 0.02% 766
2024
Q4
$659K Sell
38,416
-56,522
-60% -$1.06M 0.01% 968
2024
Q3
$1.9M Buy
94,938
+43,836
+86% +$682K 0.03% 571
2024
Q2
$571K Sell
51,102
-43,108
-46% -$362K 0.01% 965
2024
Q1
$622K Sell
94,210
-27,726
-23% -$152K 0.01% 918
2023
Q4
$551K Buy
121,936
+4,801
+4% +$17.8K 0.01% 940
2023
Q3
$419K Sell
117,135
-2,255
-2% -$8.68K 0.01% 1009
2023
Q2
$441K Sell
119,390
-6,500
-5% -$24.1K 0.01% 1024
2023
Q1
$417K Buy
125,890
+3,065
+2% +$10.6K 0.01% 1009
2022
Q4
$477K Sell
122,825
-77,500
-39% -$239K 0.01% 923
2022
Q3
$487K Buy
200,325
+30,903
+18% +$74.1K 0.01% 907
2022
Q2
$335K Buy
+169,422
New +$333K 0.01% 1064
2020
Q2
Sell
-10,836
Closed -$31K 1254
2020
Q1
$31K Buy
10,836
+810
+8% +$2.8K ﹤0.01% 1167
2019
Q4
$40K Buy
+10,026
New +$43.7K ﹤0.01% 1258

Other funds holding ADMA

Oppenheimer & Co's ADMA Position: Q1 2026 in Review

Oppenheimer & Co opened a new position in ADMA Biologics (ADMA) in Q1 2026: 61,070 shares worth $550K. The stake represents 0.01% of the portfolio and ranks #1152 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in ADMA as recently as Q3 2025.

Oppenheimer & Co first reported a position in ADMA in Q4 2019 and has held it in 17 quarters since. The position peaked at $1.9M in Q3 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Oppenheimer & Co held 61,070 shares of ADMA Biologics worth $550K as of Q1 2026.
  • ADMA Biologics was a new Oppenheimer & Co position in Q1 2026.
  • ADMA Biologics made up 0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1152 holding.
  • Oppenheimer & Co first reported a position in ADMA Biologics in Q4 2019 and has held it in 17 quarters since.
  • Oppenheimer & Co's ADMA Biologics position peaked at $1.9M in Q3 2024.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.